|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG00443255X |
| 003 |
DE-627 |
| 005 |
20230425175401.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210507s2019 xx |||||o 00| ||dan c |
| 035 |
|
|
|a (DE-627)CTG00443255X
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2018-003535-30-FR
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)2018_16
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a dan
|
| 245 |
1 |
0 |
|a IFM 2017-03
|b A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 28-02-2019, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: A Phase III Study Comparing Lenalidomide and Daratumumab (R-Dara) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy. MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 3
|
| 650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2019) vom: 30. Juni
|
| 773 |
1 |
8 |
|g year:2019
|g day:30
|g month:06
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003535-30
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2019
|b 30
|c 06
|
Klinische Studie